John Cox (Credit: Repligen)

Flag­ship merges two star­tups to build a $220M Reper­toire of T cell tech, ther­a­pies

Soon af­ter John Cox took over as CEO at Torque Ther­a­peu­tics, he reached out to Jose‑Car­los Gutiér­rez‑Ramos.

Gutiér­rez‑Ramos, who left Syn­log­ic in 2018 to join Flag­ship Pi­o­neer­ing, was lead­ing a start­up in its port­fo­lio named Co­gen Im­mune Med­i­cines. The team there was hon­ing tech­nolo­gies to de­ci­pher the im­mune synapse around T cells — tech­nolo­gies that, Cox fig­ured, could help char­ac­ter­ize the T cells and pep­tides in­volved in Torque’s can­cer ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.